Investigators at the University of Cincinnati have found a safe and effective treatment for life-threatening angioedema attacks in the emergency department.
In angioedema, patients experience a rapid swelling of the skin and subcutaneous tissues—which, in some cases, can lead to airway obstruction and suffocation. Physicians usually treat angioedema like an allergic reaction with corticosteroids and antihistamines.
But that therapy doesn’t always work for another version of the condition, thought to be caused by taking a class of drugs known as ACE inhibitors.
"ACE inhibitors are a common treatment in patients with congestive heart failure and hypertension,” says Joseph Moellman, MD, associate professor of emergency medicine. "It is also the most common etiology of patients presenting to the emergency department with angioedema.”
Moellman says there’s currently no treatment for ACE inhibitor induced (ACEI) angioedema, as the physiology of the condition is different—caused by the levels of the blood vessel-dilating peptide bradykinin in the body.
In a triple blind, placebo-controlled phase-2 trial, Moellman worked with professor of medicine and angioedema expert Jonathan Bernstein, MD, and fellow researchers at the UC Medical Center Emergency Department to study the drug Ecallantide in the treatment of ACEI angioedema that failed to respond to the conventional therapy of corticosteroids and antihistamines.
They wanted to see if Ecallantide, which has already safely treated acute attacks of hereditary angioedema, could help patients with ACEI angioedema—specifically, if it could make them eligible for discharge within four hours of treatment.
After enrolling 50 patients in the study, they found that patients treated with Ecallantide were more likely to meet discharge sooner than those receiving antihistamines and steroids—31 percent of Ecallantide patients were eligible for discharge within four hours, as compared with 21 percent of patients receiving placebos. Additionally, patients experienced few side effects from the medication.
Moellman says the data supports launching a phase-3 trial, which will enroll more patients to confirm the initial results. He is presenting the results at the annual meeting of the Society for Academic Emergency Medicine, held May 14-17 in Dallas.
Co-authors of the study include Christopher Lindsell, PhD, Kimberly Hart and Sean Collins, MD. The study was funded by Dyax, manufacturer of Ecallantide, or Kalibtor. Bernstein is a consultant and speaker for Dyax.
Kathryn Cosse | Eurek Alert!
On track to heal leukaemia
18.01.2017 | Universitätsspital Bern
Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).
Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...
10.01.2017 | Event News
09.01.2017 | Event News
05.01.2017 | Event News
18.01.2017 | Power and Electrical Engineering
18.01.2017 | Materials Sciences
18.01.2017 | Life Sciences